Correction of eIF2-dependent defects in brain protein synthesis, synaptic plasticity, and memory in mouse models of Alzheimer’s disease


BIBLIOGRAPHIC THERAPEUTIC AGENT ANIMAL MODEL EXPERIMENTAL DESIGN OUTCOMES

Bibliographic

Year of Publication:
2021
Contact PI Name:
Sergio T. Ferreira
Contact PI Affiliation:
Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Co-Authors:
Mauricio M. Oliveira, Mychael V. Lourenco, Francesco Longo, Nicole P. Kasica, Wenzhong Yang, Gonzalo Ureta, Danielle D. P. Ferreira, Paulo H. J. Mendonça, Sebastian Bernales, Tao Ma, Fernanda G. De Felice, Eric Klann
Primary Reference (PubMED ID):
Funding Source:
National Institute on Aging (NIA)
National Institute of Neurological Disorders and Stroke (NINDS)
Alzheimer's Association
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ)
Brazilian National Council for Scientific and Technological Development (CNPq)
National Institute of Translational Neuroscience (INNT/Brazil)
International Society for Neurochemistry
Study Goal and Principal Findings:

Neuronal protein synthesis is essential for long-term memory consolidation, and its dysregulation is implicated in various neurodegenerative disorders, including Alzheimer's disease (AD). Cellular stress triggers the activation of protein kinases that converge on the phosphorylation of eukaryotic translation initiation factor 2α (eIF2α), which attenuates mRNA translation. This translational inhibition is one aspect of the integrated stress response (ISR). We found that postmortem brain tissue from AD patients showed increased phosphorylation of eIF2α and reduced abundance of eIF2B, another key component of the translation initiation complex. Systemic administration of the small-molecule compound ISRIB (which blocks the ISR downstream of phosphorylated eIF2α) rescued protein synthesis in the hippocampus, measures of synaptic plasticity, and performance on memory-associated behavior tests in wild-type mice cotreated with salubrinal (which inhibits translation by inducing eIF2α phosphorylation) and in both β-amyloid-treated and transgenic AD model mice. Thus, attenuating the ISR downstream of phosphorylated eIF2α may restore hippocampal protein synthesis and delay cognitive decline in AD patients.

Bibliographic Notes:
Eric Klann (Center for Neural Science, New York University, New York, New York, USA) and Sergio T. Ferreira (Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil) are corresponding authors on this paper.

Therapeutic Agent

Therapeutic Information:
Therapy Type:
Small Molecule
Therapeutic Agent:
ISRIB
Therapeutic Target:
Eukaryotic Translation Initiation Factor 2B (eIF2B)
Therapy Type:
Small Molecule
Therapeutic Agent:
Salubrinal
Therapeutic Target:
Eukaryotic Translation Initiation Factor 2 Subunit alpha (eIF2 alpha)
Therapeutic Notes:
Eukaryotic Translation Initiation Factor 2B (eIF2B) is the mechanistic target of ISRIB. Please view Schoof et al., Elife 2021 Mar 10;10:e65703 (https://pubmed.ncbi.nlm.nih.gov/33688831/) for ISRIB-eIF2B interactions.

Animal Model

Model Information:
Species:
Mouse
Model Type:
APPxPS1
Strain/Genetic Background:
B6C3
Species:
Mouse
Model Type:
beta Amyloid Peptide Injection
Strain/Genetic Background:
C57BL/6

Experimental Design

Is the following information reported in the study?:
Power/Sample Size Calculation
Randomized into Groups
Blinded for Treatment
Blinded for Outcome Measures
Pharmacokinetic Measures
Pharmacodynamic Measures
Toxicology Measures
ADME Measures
Biomarkers
Dose
Formulation
Route of Delivery
Duration of Treatment
Frequency of Administration
Age of Animal at the Beginning of Treatment
Age of Animal at the End of Treatment
Sex as a Biological Variable
Study Balanced for Sex as a Biological Variable
Number of Premature Deaths
Number of Excluded Animals
Statistical Plan
Genetic Background
Inclusion/Exclusion Criteria Included
Conflict of Interest

Outcomes

Outcome Measured
Outcome Parameters
Behavioral
Contextual Fear Conditioning
Exploratory Activity
Morris Water Maze
Novel Object Recognition Test (NORT)
Open Field Test
Motor Function
Locomotor Activity
Path Length
Swimming Speed
Histopathology
Activated Astrocytes
Activated Microglia
beta Amyloid Deposits
beta Amyloid Load
Colocalization-Astrocytes/Microglia/Amyloid Plaques
Biochemical
Activating Transcription Factor 4 (ATF4)
Activating Transcription Factor 4 (ATF4) mRNA
Brain-beta Amyloid Peptide 42
Brain-Derived Neurotrophic Factor (BDNF)
Eukaryotic Translation Initiation Factor 2 alpha (eIF2 alpha)
phospho-Eukaryotic Translation Initiation Factor 2 alpha (phospho-eIF2 alpha)
Eukaryotic Translation Initiation Factor 2 beta (eIF2 beta)
Eukaryotic Translation Initiation Factor 2 gamma (eIF2 gamma)
Postsynaptic Density Protein 95 (PSD95)
Synaptophysin
Immunochemistry
Brain-beta Amyloid Deposits
Glial Fibrillary Acidic Protein (GFAP)
Ionized Calcium Binding Adaptor Molecule 1 (Iba1)
Protein Phosphatase 1 Regulatory Subunit 15A (PPP1R15A/GADD34)
Microscopy
Dendritic Spine Density
Spectroscopy
Liquid Chromatography with Tandem Mass Spectrometry (LC/MS/MS)
Electrophysiology
field Excitatory Postsynaptic Potential (fEPSP)
Long Term Potentiation (LTP)
Pharmacokinetics
Drug Concentration-Brain
Drug Concentration-Plasma
Toxicology
Body Weight

Source URL: http://alzped.nia.nih.gov/correction-eif2-dependent